Hepatitis C treatment in a Canadian federal correctional population: Preliminary feasibility and outcomes

Hepatitis C virus (HCV) infection is a major public health concern in Canada, which now mostly affects marginalized populations, including correctional inmates. These populations ‐ until recently ‐ have largely been excluded from HCV pharmacotherapy. We report preliminary data on HCV treatment in a federal correctional population sample in British Columbia (BC), using Pegetron combination therapy. HCV RNA results are presented at week 12 of treatment, a strong predictor of treatment outcome. Just over four‐fifths (80.8%) of inmate patients had no detectable HCV RNA at week 12; inmates with genotype 2 and 3 fared better than those with genotype 1. These preliminary results suggest that HCV treatment is feasible and promises to be efficacious in correctional populations.

[1]  J. Rehm,et al.  Injection drug use and the hepatitis C virus: Considerations for a targeted treatment approach-The case study of Canada , 2004, Journal of Urban Health.

[2]  A. Sanyal,et al.  Treatment of Chronic Hepatitis C Virus in the Virginia Department of Corrections: Can Compliance Overcome Racial Differences to Response? , 2004, American Journal of Gastroenterology.

[3]  J. Rich,et al.  Hepatitis C infection and incarcerated populations , 2004 .

[4]  J. Nelles,et al.  Prison needle exchange: lessons from a comprehensive review of international evidence and experience. , 2004 .

[5]  J. Rich,et al.  Treatment of Chronic Hepatitis C in a State Correctional Facility , 2004, Annals of Internal Medicine.

[6]  M. Manns,et al.  Early virologic response to treatment with peginterferon alfa‐2b plus ribavirin in patients with chronic hepatitis C , 2003, Hepatology.

[7]  John B. Wong,et al.  Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C , 2003 .

[8]  A. Giulivi,et al.  Hepatitis C Update , 2003, Canadian journal of public health = Revue canadienne de sante publique.

[9]  T. Hammett.  Adopting More Systematic Approaches to Hepatitis C Treatment in Correctional Facilities , 2003, Annals of Internal Medicine.

[10]  B. Romanowski,et al.  Hepatitis C Seroprevalence and Risk Behaviors in Patients Attending Sexually Transmitted Disease Clinics , 2003, Sexually transmitted diseases.

[11]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[12]  M. Backmund.  Interferontherapie während der Entzugsbehandlung , 2002 .

[13]  D. Sylvestre.  Treating hepatitis C in methadone maintenance patients: an interim analysis. , 2002, Drug and alcohol dependence.

[14]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[15]  D R Hoover,et al.  Illicit drug use in one's social network and in one's neighborhood predicts individual heroin and cocaine use. , 2001, Annals of epidemiology.

[16]  M. Backmund,et al.  Treatment of hepatitis C infection in injection drug users , 2001, Hepatology.

[17]  J. Austin,et al.  HIV, hepatitis C and risk behaviour in a Canadian medium-security federal penitentiary. Queen's University HIV Prison Study Group. , 2000, QJM : monthly journal of the Association of Physicians.

[18]  M. Sherman.  Management of viral hepatitis: clinical and public health perspectives--a consensus statement. CASL Hepatitis Consensus Group. Canadian Association for Study of the Liver. , 1997, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[19]  M. Alary,et al.  Prevalence and risk behaviours for HIV infection among inmates of a provincial prison in Quebec City , 1996, AIDS.